Editor’s Briefing: September 22, 2026

In Short. Tuesday’s metabolic tape is Roche posting competitive dual-agonist diabetes numbers while Novo’s Capital Markets Day asks restless investors to buy a Consumer Rx story and five multi-blockbusters by 2030, as Caplyta and Aqneursa widen psychiatric and rare-neuro labels and Washington layers political review onto NIH grants and childhood shots.

---

Roche’s dual agonist joins the diabetes fight

Roche reported a phase 2 hit for enicepatide (CT-388), the dual GLP-1/GIP receptor agonist acquired with Carmot Therapeutics for $2.7 billion, in people with Type 2 diabetes and overweight or obesity. At the top weekly 24 mg dose over 48 weeks, HbA1c fell 2.65%. Roche framed that as best-in-disease potential against published cross-trial benchmarks (Lilly’s Mounjaro up to 1.8% at week 40, retatrutide up to 1.94% at week 40, Novo’s Ozempic 1.6% at week 30), while noting its own readout sits eight weeks later than Lilly’s and that cross-trial comparisons are unreliable. Up to 90% of enicepatide patients reached HbA1c ≤6.5%, and 62% reached ≤5.7% (versus up to 46% on retatrutide in the cited phase 3). Mean weight loss at the high dose was 15.5% at week 48 “without a demonstrable plateau.” Safety detail is still thin. Effects were mostly mild-to-moderate gastrointestinal, with 2% discontinuing for adverse events versus none on placebo. Roche already runs three late-stage obesity trials and plans glycemic-control and cardiovascular outcomes programs in the first half of next year. Competitive numbers do not yet settle the commercial question. BMO still prefers Lilly’s retatrutide as the high-efficacy weight-loss agent after Roche’s January obesity data. (Fierce Biotech)

Novo asks investors to believe again

In London, Novo CEO Mike Doustdar opened Capital Markets Day by saying leadership “have to convince” the room there is a bright future after a bruising stretch of missed readouts, cancelled collaborations, U.S. share loss to Lilly, and a rebrand that dropped “Nordisk.” The pitch has two spines. First, a “Consumer Rx” lane where serious prescription drugs meet strong consumer demand (immune-mediated inflammatory disease, pain and addiction, women’s and men’s health), not OTC. Second, a risk-adjusted promise to launch at least five multi-blockbusters by 2030, building toward more than 150 billion Danish kroner (about $23 billion) in combined sales within a decade, as semaglutide’s U.S. patent cliff approaches in 2032. Pipeline props include CagriSema (cagrilintide plus semaglutide), with Novo saying a new diabetes weight-loss study beat Lilly’s tirzepatide (BioPharma Dive notes the comparator was the second-lowest Lilly dose), hemophilia bispecific denecimig, and long-acting GLP-1/amylin zenagamtide as shot and pill. Investors were not soothed. Shares slid roughly 7–8% on the open. Growth guidance looked close to what the street had already priced. (Fierce Biotech; BioPharma Dive; BioSpace)

Caplyta aims at bipolar mania

Johnson & Johnson said Caplyta (lumateperone) 42 mg met its primary endpoint in phase 3 Study 451 in adults with manic episodes associated with bipolar I disorder (with or without mixed features). Versus placebo over three weeks, Caplyta delivered a 4.8-point greater reduction on the Young Mania Rating Scale, with J&J flagging significant improvement from day 3 and clinical response in 45.8% versus 20.9% on placebo. Overall illness severity also improved on a key secondary. No new safety signals beyond Caplyta’s known profile. A second mania phase 3 has completed. Analysis is ongoing. Caplyta already carries labels in schizophrenia, bipolar depression, and as add-on in major depressive disorder after J&J’s $14.6 billion Intra-Cellular buy. Mania is crowded (lithium, carbamazepine, valproate, other atypicals). The commercial claim is faster control with a tolerability profile patients already know from depression. (Fierce Pharma)

First labeled therapy for ataxia-telangiectasia

The FDA expanded IntraBio’s Aqneursa to ataxia-telangiectasia (A-T), making it the first treatment indicated for the ATM-driven neurodegenerative disease that typically appears in early childhood (about 1 in 40,000 worldwide). The phase 3 IB1001-303 crossover in 73 patients ages 4–50 showed a nearly 2-point SARA improvement versus placebo by week 12, and a 0.6-point edge on FDA’s preferred functional SARA (gait, sitting, stance, speech). No serious adverse events. No discontinuations for side effects. Clearance covers children and adults over 15 kg as an oral suspension. Aqneursa’s first nod was 2024 for Niemann-Pick type C. How the chemically altered amino acid helps either disease remains unclear. IntraBio suspects corrected brain energy metabolism rather than a gene-specific fix. List cost can run about $15,000 every one to two weeks. The company says it runs a financial support program. (Fierce Pharma)

Capital footnotes: AI IPO, aging kinase sale

Iambic Therapeutics filed IPO paperwork without share count or price, aiming to fund oral brain-penetrant HER2 TKI IAM1363 (phase 1 now, registrational start early 2027) plus clinic entry for KIF18A inhibitor IAM217 and CDK2/4 dual IAM-C1. Cash was $207.9 million at end-June. Headcount 171. Partners already include Takeda (up to $1.7 billion biobucks), Revolution Medicines, Jazz, Lundbeck, Nvidia, Bayer, and AbbVie. Separately, Bayer is selling Stivarga (regorafenib) to Grünenthal for up to €375 million ($431 million). China volume-based procurement already cut first-half Stivarga sales 18% to €148 million. EU exclusivity runs toward 2029, U.S. toward 2030. Grünenthal expects roughly €100 million EBITDA contribution next year and close by end-2026 or early 2027. (Fierce Biotech; Fierce Pharma)

Policy / public-health sidebar

Multiple outlets report that senior Trump officials met in the Oval Office Friday on a draft executive order for an external political commission that could veto NIH grants judged out of step with administration priorities. OMB director Russell Vought led the critique that NIH still funds “woke” work. NIH director Jay Bhattacharya defended scientific review and, per Politico, refused a request to cut Harvard funding. Congress members have already pushed back (STAT+ title noted). Separately, Trump floated splitting some childhood immunizations into five “20% doses” every six months, claiming a “massive reduction in autism” despite the thoroughly rebutted vaccine-autism link. Paul Offit told CNN such splitting would blunt efficacy without adding safety. Merck restated support for evidence-based immunization policy. BioPharma Dive’s Tuesday analysis of most-favored-nation deals warns the confidential company pacts could shrink projected Medicare savings under proposed GLOBE/GUARD models by nearly 80% if signatories claim exemption. China’s new five-year pharma plan targets at least 25% of global first-in-class drugs by 2030, 50 domestic firms above 10 billion yuan in sales, and five global blockbusters. (Fierce Biotech; Fierce Pharma; STAT News; BioPharma Dive; Fierce Biotech)

What to watch

pdufa.bio now lists Merck Winrevair (sotatercept) HYPERION (recently diagnosed PAH label update) as Awaiting after the September 21 goal date (days-to-decision −1), with no public decision logged yet. Next: Mirum/Incyte zilurgisertib (FOP) September 26. October: Roche Tecentriq adjuvant MSI-H/stage III colon (October 9), Merck/Daiichi I-DXd ES-SCLC (October 10), Roche Enspryng TED (October 15), Viatris/Opus MR-141 phentolamine ophthalmic (October 17). BioProcess International’s Boston conference runs September 22–25. Overnight BPI hard-news remained thin beyond the same Sanofi Toronto Fluzone High-Dose facility and Merck KGaA Bengaluru hub notes carried yesterday. (pdufa.bio; BioProcess International)